written on 07.05.2014

Payers fret about the next drug doomsday: Pricey PCSK9 cholesterol meds


Which group of hotly anticipated, next-generation therapies for a widespread health problem is expected to cost payers beaucoup bucks when they hit the market? If you said the new crop of hepatitis C treatments, you'd be half right.